MX2013008713A - Metodos para tratar taquicarida y/o controlar la frecuencia cardiaca, minimizando y/o controlando al mismo tiempo la hipotesis. - Google Patents

Metodos para tratar taquicarida y/o controlar la frecuencia cardiaca, minimizando y/o controlando al mismo tiempo la hipotesis.

Info

Publication number
MX2013008713A
MX2013008713A MX2013008713A MX2013008713A MX2013008713A MX 2013008713 A MX2013008713 A MX 2013008713A MX 2013008713 A MX2013008713 A MX 2013008713A MX 2013008713 A MX2013008713 A MX 2013008713A MX 2013008713 A MX2013008713 A MX 2013008713A
Authority
MX
Mexico
Prior art keywords
controlling
minimizing
methods
heart rate
hypotension
Prior art date
Application number
MX2013008713A
Other languages
English (en)
Inventor
Barrett Rabinow
Jeff Mckee
Original Assignee
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Healthcare Sa filed Critical Baxter Healthcare Sa
Publication of MX2013008713A publication Critical patent/MX2013008713A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describe un método para tratar taquicardia, minimizando y/o controlando al mismo tiempo la hipotensión asociada con dicho tratamiento, que incluye administrar una cantidad terapéuticamente efectiva de una composición farmacéutica que comprende el S-isómero de esmolol a un sujeto que necesita del mismo.
MX2013008713A 2011-01-27 2012-01-26 Metodos para tratar taquicarida y/o controlar la frecuencia cardiaca, minimizando y/o controlando al mismo tiempo la hipotesis. MX2013008713A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161436992P 2011-01-27 2011-01-27
PCT/US2012/022696 WO2012103314A1 (en) 2011-01-27 2012-01-26 Methods of treating tachycardia and/or controlling heart rate while minimizing and/or controlling hypotension

Publications (1)

Publication Number Publication Date
MX2013008713A true MX2013008713A (es) 2013-08-29

Family

ID=45567141

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013008713A MX2013008713A (es) 2011-01-27 2012-01-26 Metodos para tratar taquicarida y/o controlar la frecuencia cardiaca, minimizando y/o controlando al mismo tiempo la hipotesis.

Country Status (10)

Country Link
US (2) US8686036B2 (es)
EP (1) EP2667867B1 (es)
JP (1) JP2014505074A (es)
KR (1) KR20140034729A (es)
CN (1) CN103338763A (es)
AU (1) AU2012211318C1 (es)
BR (1) BR112013016701A2 (es)
CA (1) CA2825311A1 (es)
MX (1) MX2013008713A (es)
WO (1) WO2012103314A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013018598A2 (pt) 2011-01-27 2016-10-18 Baxter Healthcare Sa composição farmacêutica, método para tratar uma doença cardíaca, uso de (s)-metil-3-[4-(2-hidroxi-3-[4-(2-hidroxi-3-isopropilamino) propoxi] fenilpropionato, e, método para controlar frequência cardíaca
RU2613564C1 (ru) * 2015-12-02 2017-03-17 федеральное государственное бюджетное образовательное учреждение высшего образования "Северо-Западный государственный медицинский университет имени И.И. Мечникова" Министерства здравоохранения Российской Федерации (ФГБОУ ВО СЗГМУ им. И.И. Мечникова Минздрава России) Способ прогнозирования интраоперационной артериальной гипотензии при проведении анестезии

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0179808B1 (en) 1984-04-09 1991-10-30 The Du Pont Merck Pharmaceutical Company Pharmaceutical composition suitable for treatment or prophylaxis of cardiac disorders
CA1282787C (en) * 1985-12-04 1991-04-09 Ghanshyam Patil Synthesis of aryloxypropanolamines and arylethanolamines
JP2521317B2 (ja) * 1986-09-02 1996-08-07 ザ・デュポン・メルク・ファーマシュウティカル・カンパニー ｄｌ―メチル３―［４―（２―ヒドロキシ―３―イソプロピルアミノ）プロポキシ］フエニルプロピオネ―ト［（ｄｌ―エスモロ―ル）］の分割
US4857552A (en) 1988-06-08 1989-08-15 E. I. Du Pont De Nemours And Co. Stable pharmaceutical composition
US5849843A (en) 1993-11-16 1998-12-15 Baxter International Inc. Polymeric compositions for medical packaging and devices
US5998019A (en) 1993-11-16 1999-12-07 Baxter International Inc. Multi-layered polymer structure for medical products
US5977409A (en) * 1997-04-15 1999-11-02 University Of Toledo Method of using α-substituted benzylamine chiral auxiliary synthetic reagents
TWI277414B (en) * 2001-01-12 2007-04-01 Baxter Int Esmolol formulation
US6310094B1 (en) 2001-01-12 2001-10-30 Baxter International Inc. Ready-to-use esmolol solution
US20060286037A1 (en) * 2003-08-08 2006-12-21 Ono Pharmaceutical Co., Ltd. Heart-slowing drug containing short-acting ß blocker as the active ingredient
US20080293814A1 (en) * 2007-05-22 2008-11-27 Deepak Tiwari Concentrate esmolol
CN101323580A (zh) 2008-07-25 2008-12-17 河北科技大学 手性芳氧丙醇胺类化合物及其盐的合成方法
CN101881755B (zh) 2009-05-04 2013-05-29 南京海辰药业有限公司 通过高效液相色谱法检测盐酸艾司洛尔光学异构体的方法
CN101891636A (zh) 2009-05-21 2010-11-24 南京海辰药业有限公司 制备盐酸艾司洛尔光学异构体的新方法
CN102106846A (zh) 2009-12-23 2011-06-29 南京海辰药业有限公司 左旋盐酸艾司洛尔药物组合物及其制备方法
BR112013018598A2 (pt) 2011-01-27 2016-10-18 Baxter Healthcare Sa composição farmacêutica, método para tratar uma doença cardíaca, uso de (s)-metil-3-[4-(2-hidroxi-3-[4-(2-hidroxi-3-isopropilamino) propoxi] fenilpropionato, e, método para controlar frequência cardíaca

Also Published As

Publication number Publication date
WO2012103314A1 (en) 2012-08-02
KR20140034729A (ko) 2014-03-20
US9084763B2 (en) 2015-07-21
US8686036B2 (en) 2014-04-01
US20140066503A1 (en) 2014-03-06
CN103338763A (zh) 2013-10-02
CA2825311A1 (en) 2012-08-02
AU2012211318C1 (en) 2016-08-04
AU2012211318A1 (en) 2013-05-02
US20120302637A1 (en) 2012-11-29
AU2012211318B2 (en) 2016-01-28
JP2014505074A (ja) 2014-02-27
EP2667867B1 (en) 2015-05-27
BR112013016701A2 (pt) 2017-07-04
EP2667867A1 (en) 2013-12-04

Similar Documents

Publication Publication Date Title
PH12018501410A1 (en) Therapeutically active compounds and their method of use
MX2017004471A (es) Compuestos de triazolopiridina y métodos para el tratamiento de fibrosis cística.
MX365950B (es) Compuestos de piridazinona y metodos para el tratamiento de la fibrosis quistica.
NZ631144A (en) Compositions and methods for transmucosal absorption
NZ630805A (en) Pharmaceutical combinations comprising a thionucleotide analog
WO2014004861A3 (en) Methods of treating pediatric metabolic syndrome
EA201490004A1 (ru) Применение bifidobacterium lactis bl-04 для лечения заболеваний дыхательных путей
GB201111485D0 (en) Drug composition and its use in therapy
MX2014001050A (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero.
SG195110A1 (en) Pirfenidone and anti-fibrotic therapy in selected patients
IN2015DN00450A (es)
NZ701607A (en) Therapeutic use of chardonnay seed products
MX350666B (es) Composiciones y sus usos para tratar hiperuricemia y trastornos metabolicos asociados con hiperuricemia.
MX360030B (es) Metodos para tratar el trastorno bipolar.
MX2014006762A (es) Metodos para el tratamiento de desordenes cardiovasculares.
MX2013008715A (es) Uso de (s) -esmolol para controlar la irritacion venosa asociada con el tratamiento de un padecimiento cardiaco.
WO2014153385A3 (en) Methods of treating metabolic disorders
MX2015000485A (es) Tratamiento de esclerosis multiple con una combinacion de laquinimod y fampridina.
IN2014MN02269A (es)
HK1255501A1 (zh) 胺羧基硼烷作為一氧化碳的治療性輸送和作為活性氧存在下的一般藥物輸送系統的用途
WO2013083826A3 (en) Glp-1 agonists
MX2013008713A (es) Metodos para tratar taquicarida y/o controlar la frecuencia cardiaca, minimizando y/o controlando al mismo tiempo la hipotesis.
JP2014526564A5 (es)
MX2014014814A (es) Composicion farmaceutica para el tratamiento de inflamacion y dolor.
MX348723B (es) Combinaciones de solifenacina y estimulantes salivales para el tratamiento de la vejiga hiperactiva.

Legal Events

Date Code Title Description
FG Grant or registration